Takeda Pharmaceuticals U.S.A., Inc. or TPUSA (TKPYY.PK) and Affymax, Inc. (AFFY) Monday said Takeda Pharmaceuticals America, Inc. or TPA has entered into a supply agreement for sourcing and supply of Omontys (peginesatide) Injection with DSI Renal, one of the largest dialysis providers in the U.S. Financial terms were not disclosed.
Omontys is the only once-monthly erythropoiesis-stimulating agent for anemia available to the adult dialysis patient population with chronic kidney disease in the U.S.
The agreement allows DSI Renal to purchase Omontys for use within its organization and provides for discounts and rebates on the product. DSI Renal has indicated that it plans to initially evaluate Omontys in selected centers, and then, based on experience, evaluate the potential to expand to additional centers.
Omontys was approved by the U.S. Food and Drug Administration on March 27, 2012, for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.